DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells
Author:
Affiliation:
1. Southern Medical University Affiliated Fengxian Hospital, Shanghai, Shanghai, P.R. China;
2. Tengzhou Central People's Hospital, Tengzhou, Shandong Province, P.R. China;
3. Shanghai University of Medicine & Health Sciences, Shanghai, P.R. China
Publisher
Informa UK Limited
Subject
Pharmaceutical Science,Biomedical Engineering,General Medicine,Medicine (miscellaneous),Biotechnology
Link
https://www.tandfonline.com/doi/pdf/10.1080/21691401.2019.1652624
Reference30 articles.
1. The Pathobiology of Diabetic Complications
2. Standards of Medical Care for Patients With Diabetes Mellitus
3. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
4. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
5. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. DPP-4i versus SGLT2i as modulators of PHD3/HIF-2α pathway in the diabetic kidney;Biomedicine & Pharmacotherapy;2023-11
2. HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility;Hepatology International;2022-12-12
3. HMGCL-induced β-Hydroxybutyrate Production Attenuates Hepatocellular Carcinoma via DPP4-mediated Ferroptosis Susceptibility;2022-09-20
4. Identification of Adamts4 as a novel adult cardiac injury biomarker with therapeutic implications in patients with cardiac injuries;Scientific Reports;2022-06-14
5. Systematic transcriptomic and phenotypic characterization of human and murine cardiac myocyte cell lines and primary cardiomyocytes reveals serious limitations and low resemblances to adult cardiac phenotype;Journal of Molecular and Cellular Cardiology;2022-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3